FindMyKOL
Clinical trialNCT01990560CompletedPhase 4Interventional

Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism

NCT01990560 is a phase 4 interventional trial sponsored by Icahn School of Medicine at Mount Sinai. As of 21 Nov 2026, it is completed. It studies Mifepristone in Mild Hypercortisolism. The registry lists an enrollment of 8 participants at 1 site in 1 country. The registry lists a start date of 30 Nov 2013 and a primary completion date of 30 Sept 2016.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01990560
FieldValue
Registry IDNCT01990560
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorIcahn School of Medicine at Mount Sinai
Enrollment8
Registered sites1
Countries1
ConditionsMild Hypercortisolism
DrugsMifepristone
Start30 Nov 2013
Primary completion30 Sept 2016
Study completion30 Sept 2016
Last update posted2 Mar 2018

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether mifepristone is an effective treatment for hyperglycemia due to mild hypercortisolism. * To test the hypothesis that GR blockade with mifepristone will decrease the severity of metabolic syndrome features as measured by waist circumference, lipid profile, body mass index, blood pressure and insulin resistance, measured by HOMA-IR score. * To test the hypothesis that GR blockade with mifepristone will improve QoL, depression and anxiety scores, measured by validated assessments, in patients with mild hypercortisolism.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Icahn School of Medicine at Mount Sinai

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01990560

Each answer restates registry values shown on this page.

What is NCT01990560?

NCT01990560 is a phase 4 interventional trial sponsored by Icahn School of Medicine at Mount Sinai. It studies Mifepristone in Mild Hypercortisolism.

Who leads NCT01990560?

The registry names Alice C Levine, MD (principal investigator, Icahn School of Medicine at Mount Sinai) as the overall official.

Where does NCT01990560 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01990560 study?

The registered drug and biological interventions are Mifepristone.

When did NCT01990560 end?

The registry lists a primary completion date of 30 Sept 2016 and a study completion date of 30 Sept 2016. The sponsor last updated the record on 2 Mar 2018.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.